Medicare Coverage Set for Genomic Health's Oncotype Dx Colon Cancer Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genomic Health today announced it has attained Medicare coverage for its Oncotype Dx colon cancer test.

Palmetto GBA, the designated national contractor for the test, has created a formal coverage policy for all Medicare recipients with stage II colon cancer. The policy is effective for all claims for services performed on or after Sept. 18, the Redwood City, Calif.-based genomics testing service firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.